Alberico Luigi Catapano, Italy
University of Milan " Department of Pharmacological and Biomolecular Sciences Department of Pharmacological and Biomolecular Sciences
Moderator of 3 Sessions
Session Time
17:00 - 18:30
Session Evaluation
Option 1
[{"name":"Introduction","mode":"playlist","public":true,"info":{"id":1580,"presentation":"Introduction","session":"Novel approaches to lipid lowering management","presenter":"Alberico Luigi Catapano, Italy","photo":""},"playlist":[{"name":"1580-Introduction","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/105\/EAS201580.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/105\/EAS201580.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/105\/5FF2F12B.jpg","data":[],"tracks":[]}]},{"name":"What is the landscape on lipid management today?","mode":"playlist","public":true,"info":{"id":1505,"presentation":"What is the landscape on lipid management today?","session":"Novel approaches to lipid lowering management","presenter":"Lale Tokg\u00f6zo\u011flu, Turkey","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/5284.jpg"},"playlist":[{"name":"1505 - What is the landscape on lipid management today?","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/105\/105_1505_2.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/105\/105_1505_2.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/105\/593A446A.jpg","data":[],"tracks":[]}]},{"name":"When do we need add on therapies to statin?","mode":"playlist","public":true,"info":{"id":1506,"presentation":"When do we need add on therapies to statin?","session":"Novel approaches to lipid lowering management","presenter":"Ulrich Laufs, Germany","photo":""},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/105\/Ulrich Laufs - EAS20-1506-When Do We Need Add on Therapies to Statin.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/105\/Ulrich Laufs - EAS20-1506-When Do We Need Add on Therapies to Statin.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/105\/7EA9942E.jpg","data":[],"tracks":[]}]},{"name":"What do we know so far about bempedoic acid?","mode":"playlist","public":true,"info":{"id":1507,"presentation":"What do we know so far about bempedoic acid?","session":"Novel approaches to lipid lowering management","presenter":"Kausik K. Ray, United Kingdom","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/1332.jpg"},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/105\/Kausik Ray - EAS20- 1507- What do we know so far about bempedoic acid.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/105\/Kausik Ray - EAS20- 1507- What do we know so far about bempedoic acid.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/105\/AED7C78A.jpg","data":[],"tracks":[]}]},{"name":"Panel Discussion with Live Q&A","mode":"playlist","public":true,"info":{"id":1581,"presentation":"Panel Discussion with Live Q&A","session":"Novel approaches to lipid lowering management","presenter":"Marja-Riitta Taskinen, Finland, Alberico Luigi Catapano, Italy, Lale Tokg\u00f6zo\u011flu, Turkey, Ulrich Laufs, Germany, Kausik K. Ray, United Kingdom","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/5369.jpg"},"playlist":[{"name":"Novel approaches to lipid lowering management","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/105\/Novel approaches to lipid lowering management.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/105\/Novel approaches to lipid lowering management.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/105\/D568E245.jpg","data":[],"tracks":[]}]}]
{"type":2,"code":"7E32Xi02P"}
[session]
[presentation]
[presenter]
Session Time
08:30 - 09:53
Session Evaluation
Option 1
[{"name":"Introduction","mode":"playlist","public":true,"info":{"id":1551,"presentation":"Introduction","session":"UNDERSTANDING BIOLOGY FOR CLINICAL APPLICATION","presenter":"Alberico Luigi Catapano, Italy","photo":""},"playlist":[{"name":"1551-Introduction","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/19\/EAS201551.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/19\/EAS201551.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/19\/9235A32A.jpg","data":[],"tracks":[]}]},{"name":"The lipoprotein(a) story - from risk factor to causality to clinical trials","mode":"playlist","public":true,"info":{"id":1440,"presentation":"The lipoprotein(a) story - from risk factor to causality to clinical trials","session":"UNDERSTANDING BIOLOGY FOR CLINICAL APPLICATION","presenter":"Sotirios Tsimikas, United States of America","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/5288.jpg"},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/19\/Dr. Sotirios Sam Tsimikas - EAS20- 1440 -The lipoprotein(a) story - from risk factor to causality to clinical trials.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/19\/Dr. Sotirios Sam Tsimikas - EAS20- 1440 -The lipoprotein(a) story - from risk factor to causality to clinical trials.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/19\/491E1C2.jpg","data":[],"tracks":[]}]},{"name":"Immune modulation in atherosclerosis","mode":"playlist","public":true,"info":{"id":1441,"presentation":"Immune modulation in atherosclerosis","session":"UNDERSTANDING BIOLOGY FOR CLINICAL APPLICATION","presenter":"Ziad Mallat, United Kingdom","photo":""},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/19\/Ziad Mallat - EAS20 - 1441 - Immune modulation in atherosclerosis.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/19\/Ziad Mallat - EAS20 - 1441 - Immune modulation in atherosclerosis.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/19\/1EEE01A7.jpg","data":[],"tracks":[]}]},{"name":"Prevention of cardiovascular diseases by glucose lowering drugs","mode":"playlist","public":true,"info":{"id":1442,"presentation":"Prevention of cardiovascular diseases by glucose lowering drugs","session":"UNDERSTANDING BIOLOGY FOR CLINICAL APPLICATION","presenter":"Stefano Del Prato, Italy","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/5316.jpg"},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/19\/Stefano Del Prato - EAS20 - 1442 - Prevention of cardiovascular diseases by glucose lowering drugs.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/19\/Stefano Del Prato - EAS20 - 1442 - Prevention of cardiovascular diseases by glucose lowering drugs.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/19\/9713E339.jpg","data":[],"tracks":[]}]},{"name":"Will non-coding RNAs change our understanding of vascular biology and disease?","mode":"playlist","public":true,"info":{"id":1443,"presentation":"Will non-coding RNAs change our understanding of vascular biology and disease?","session":"UNDERSTANDING BIOLOGY FOR CLINICAL APPLICATION","presenter":"Stephanie Dimmeler, Germany","photo":""},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/19\/Prof. Dr. Stefanie Dimmeler - EAS20 - 1443 - Will non-coding RNAs change our understanding of vascular biology and disease.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/19\/Prof. Dr. Stefanie Dimmeler - EAS20 - 1443 - Will non-coding RNAs change our understanding of vascular biology and disease.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/19\/990A4258.jpg","data":[],"tracks":[]}]}]
{"type":2,"code":"6E32Xi0k"}
[session]
[presentation]
[presenter]
Date
07.10.2020, Wednesday
Session Time
17:30 - 19:00
Session Evaluation
Option 1
[{"name":"Introduction","mode":"playlist","public":true,"info":{"id":1751,"presentation":"Introduction","session":"Lowering circulating PCSK9 to reduce LDL cholesterol: Current approaches","presenter":"Alberico Luigi Catapano, Italy","photo":""},"playlist":[{"name":"1751-Introduction","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/163\/EAS201751.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/163\/EAS201751.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/163\/38F8677A.jpg","data":[],"tracks":[]}]},{"name":"The biology of PCSK9","mode":"playlist","public":true,"info":{"id":1752,"presentation":"The biology of PCSK9","session":"Lowering circulating PCSK9 to reduce LDL cholesterol: Current approaches","presenter":"Bertrand Cariou, France","photo":""},"playlist":[{"name":"1752-The biology of PCSK9","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/163\/EAS201752.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/163\/EAS201752.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/163\/7F581DAA.jpg","data":[],"tracks":[]}]},{"name":"Monoclonal antibody approaches targeting circulating PCSK9","mode":"playlist","public":true,"info":{"id":1753,"presentation":"Monoclonal antibody approaches targeting circulating PCSK9","session":"Lowering circulating PCSK9 to reduce LDL cholesterol: Current approaches","presenter":"Ulf Landmesser, Germany","photo":""},"playlist":[{"name":"1753-Monoclonal antibody approaches targeting circulating PCSK9","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/163\/EAS20_1753.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/163\/EAS20_1753.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/163\/8CA46531.jpg","data":[],"tracks":[]}]},{"name":"siRNA based approaches targeting hepatic synthesis of PCSK9","mode":"playlist","public":true,"info":{"id":1754,"presentation":"siRNA based approaches targeting hepatic synthesis of PCSK9","session":"Lowering circulating PCSK9 to reduce LDL cholesterol: Current approaches","presenter":"Kausik K. Ray, United Kingdom","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/1332.jpg"},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/163\/Kausik Ray - EAS20 - 1754.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/163\/Kausik Ray - EAS20 - 1754.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/163\/32304323.jpg","data":[],"tracks":[]}]},{"name":"Panel Discussion with Live Q&A","mode":"playlist","public":true,"info":{"id":1755,"presentation":"Panel Discussion with Live Q&A","session":"Lowering circulating PCSK9 to reduce LDL cholesterol: Current approaches","presenter":"Lale Tokg\u00f6zo\u011flu, Turkey, Alberico Luigi Catapano, Italy, Bertrand Cariou, France, Ulf Landmesser, Germany, Kausik K. Ray, United Kingdom","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/5284.jpg"},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/163\/Lowering circulating PCSK9 to reduce LDL cholesterol.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/163\/Lowering circulating PCSK9 to reduce LDL cholesterol.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/163\/39D8742F.jpg","data":[],"tracks":[]}]}]
{"type":2,"code":"aE32Xi03P"}
[session]
[presentation]
[presenter]
Presenter of 10 Presentations
Welcome and introduction
Session Type
Industry Sponsored Session
Date
07.10.2020, Wednesday
Session Time
16:00 - 17:30
Lecture Time
16:00 - 16:10
[{"name":"Welcome and introduction","mode":"playlist","public":true,"info":{"id":1739,"presentation":"Welcome and introduction","session":"Not included in the main CME-CPD of the event","presenter":"Alberico Luigi Catapano, Italy","photo":""},"playlist":[{"name":"Welcome and introductionWelcome and introduction","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/24\/Video 1 - EAS Virtual Congress - Prof Catapano.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/24\/Video 1 - EAS Virtual Congress - Prof Catapano.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/24\/2492AEED.jpg","data":[],"tracks":[]}]}]
{"provider":"CTI","provider_live":0,"type":1,"code":"aE22Xi0vZ"}
[session]
[presentation]
[presenter]
Panel discussion & Conclusion
Session Type
Industry Sponsored Session
Date
07.10.2020, Wednesday
Session Time
16:00 - 17:30
Lecture Time
16:55 - 17:30
[{"name":"Panel discussion & Conclusion","mode":"playlist","public":true,"info":{"id":1743,"presentation":"Panel discussion & Conclusion","session":"Not included in the main CME-CPD of the event","presenter":"Alberico Luigi Catapano, Italy, Fran\u00e7ois Mach, Switzerland, Ulrich Laufs, Germany","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/99.jpg"},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/24\/Add on to take back control Combining lipid-0.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/24\/Add on to take back control Combining lipid-0.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/24\/EDE0A2.jpg","data":[],"tracks":[]}]}]
{"provider":"CTI","provider_live":0,"type":1,"code":"9E22Xi0w4"}
[session]
[presentation]
[presenter]
Introduction
Date
07.10.2020, Wednesday
Session Time
17:30 - 19:00
Lecture Time
17:30 - 17:33
[{"name":"Introduction","mode":"playlist","public":true,"info":{"id":1751,"presentation":"Introduction","session":"Lowering circulating PCSK9 to reduce LDL cholesterol: Current approaches","presenter":"Alberico Luigi Catapano, Italy","photo":""},"playlist":[{"name":"1751-Introduction","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/163\/EAS201751.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/163\/EAS201751.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/163\/38F8677A.jpg","data":[],"tracks":[]}]}]
{"provider":"CTI","provider_live":0,"type":1,"code":"7E22Xi0wc"}
[session]
[presentation]
[presenter]
Panel Discussion with Live Q&A
Date
07.10.2020, Wednesday
Session Time
17:30 - 19:00
Lecture Time
18:33 - 18:48
[{"name":"Panel Discussion with Live Q&A","mode":"playlist","public":true,"info":{"id":1755,"presentation":"Panel Discussion with Live Q&A","session":"Lowering circulating PCSK9 to reduce LDL cholesterol: Current approaches","presenter":"Lale Tokg\u00f6zo\u011flu, Turkey, Alberico Luigi Catapano, Italy, Bertrand Cariou, France, Ulf Landmesser, Germany, Kausik K. Ray, United Kingdom","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/5284.jpg"},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/163\/Lowering circulating PCSK9 to reduce LDL cholesterol.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/163\/Lowering circulating PCSK9 to reduce LDL cholesterol.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/163\/39D8742F.jpg","data":[],"tracks":[]}]}]
{"provider":"CTI","provider_live":0,"type":1,"code":"6E22Xi0wg"}
[session]
[presentation]
[presenter]
Therapeutic Approaches - The EAS way
Session Type
Joint symposium
Session Time
14:30 - 15:30
Lecture Time
15:00 - 15:15
[{"name":"Therapeutic Approaches - The EAS way","mode":"playlist","public":true,"info":{"id":1528,"presentation":"Therapeutic Approaches - The EAS way","session":"NLA\/EAS joint session - Dyslipidemia Treatment in Light of the New Guidelines","presenter":"Alberico Luigi Catapano, Italy","photo":""},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/2\/Alberico L. Catapano - EAS20 - 1528 - Therapeutic Approaches - The EAS way.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/2\/Alberico L. Catapano - EAS20 - 1528 - Therapeutic Approaches - The EAS way.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/2\/757174.jpg","data":[],"tracks":[]}]}]
{"provider":"CTI","provider_live":0,"type":1,"code":"9E22Xi0sm"}
[session]
[presentation]
[presenter]
Introduction
Session Time
17:00 - 18:30
Lecture Time
17:00 - 17:03
[{"name":"Introduction","mode":"playlist","public":true,"info":{"id":1580,"presentation":"Introduction","session":"Novel approaches to lipid lowering management","presenter":"Alberico Luigi Catapano, Italy","photo":""},"playlist":[{"name":"1580-Introduction","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/105\/EAS201580.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/105\/EAS201580.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/105\/5FF2F12B.jpg","data":[],"tracks":[]}]}]
{"provider":"CTI","provider_live":0,"type":1,"code":"6E22Xi0tf"}
[session]
[presentation]
[presenter]
Panel Discussion with Live Q&A
Session Time
17:00 - 18:30
Lecture Time
17:45 - 18:00
[{"name":"Panel Discussion with Live Q&A","mode":"playlist","public":true,"info":{"id":1581,"presentation":"Panel Discussion with Live Q&A","session":"Novel approaches to lipid lowering management","presenter":"Marja-Riitta Taskinen, Finland, Alberico Luigi Catapano, Italy, Lale Tokg\u00f6zo\u011flu, Turkey, Ulrich Laufs, Germany, Kausik K. Ray, United Kingdom","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/5369.jpg"},"playlist":[{"name":"Novel approaches to lipid lowering management","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/105\/Novel approaches to lipid lowering management.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/105\/Novel approaches to lipid lowering management.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/105\/D568E245.jpg","data":[],"tracks":[]}]}]
{"provider":"CTI","provider_live":0,"type":1,"code":"7E22Xi0tg"}
[session]
[presentation]
[presenter]
What is the critical evidence behind the guideline:
Session Type
Joint symposium
Session Time
10:00 - 11:10
Lecture Time
10:22 - 10:36
[{"name":"What is the critical evidence behind the guideline:","mode":"playlist","public":true,"info":{"id":1424,"presentation":"What is the critical evidence behind the guideline:","session":"ESC-EAS joint symposium - A Deep Dive into ESC\/EAS Dyslipidemia Guidelines","presenter":"Alberico Luigi Catapano, Italy","photo":""},"playlist":[{"name":"What is the critical evidence","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/8\/20.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/8\/20.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/8\/685A78AF.jpg","data":[],"tracks":[]}]}]
{"provider":"CTI","provider_live":0,"type":1,"code":"aE22Xi0qy"}
[session]
[presentation]
[presenter]
What is the critical evidence behind the guideline:
Session Type
Joint symposium
Session Time
10:00 - 11:10
Lecture Time
10:55 - 11:09
[{"name":"What is the critical evidence behind the guideline:","mode":"playlist","public":true,"info":{"id":1426,"presentation":"What is the critical evidence behind the guideline:","session":"ESC-EAS joint symposium - A Deep Dive into ESC\/EAS Dyslipidemia Guidelines","presenter":"Alberico Luigi Catapano, Italy","photo":""},"playlist":[{"name":"1426-What is the critical evidence behind the guideline:","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/8\/EAS201426.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/8\/EAS201426.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/8\/E1EAE43A.jpg","data":[],"tracks":[]}]}]
{"provider":"CTI","provider_live":0,"type":1,"code":"7E22Xi0qA"}
[session]
[presentation]
[presenter]
Introduction
Session Time
08:30 - 09:53
Lecture Time
08:30 - 08:33
[{"name":"Introduction","mode":"playlist","public":true,"info":{"id":1551,"presentation":"Introduction","session":"UNDERSTANDING BIOLOGY FOR CLINICAL APPLICATION","presenter":"Alberico Luigi Catapano, Italy","photo":""},"playlist":[{"name":"1551-Introduction","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/19\/EAS201551.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/19\/EAS201551.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/19\/9235A32A.jpg","data":[],"tracks":[]}]}]
{"provider":"CTI","provider_live":0,"type":1,"code":"7E22Xi0sK"}
[session]
[presentation]
[presenter]
